477 related articles for article (PubMed ID: 26472278)
1. Apremilast in psoriatic arthritis.
Schett G
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
[TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
3. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED
Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
[TBL] [Abstract][Full Text] [Related]
4. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
5. Apremilast in the treatment of psoriasis and psoriatic arthritis.
Gooderham M; Papp K
Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
[TBL] [Abstract][Full Text] [Related]
6. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
7. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
[TBL] [Abstract][Full Text] [Related]
8. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
9. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
11. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
12. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Schafer PH; Chen P; Fang L; Wang A; Chopra R
J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
[TBL] [Abstract][Full Text] [Related]
13. Apremilast (otezla) for psoriatic arthritis.
Med Lett Drugs Ther; 2014 May; 56(1443):41-2. PubMed ID: 24869713
[No Abstract] [Full Text] [Related]
14. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
17. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
20. Apremilast and its role in psoriatic arthritis.
Sandhu VK; Eder L; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
